other material
confidence high
sentiment positive
materiality 0.80
Agios sells vorasidenib royalty rights to Royalty Pharma for $905M upfront upon FDA approval
AGIOS PHARMACEUTICALS, INC.
- Royalty Pharma pays $905M to Agios upon FDA approval of vorasidenib (PDUFA date Aug 20, 2024).
- Agios retains $200M milestone from Servier upon approval; total potential cash inflow of ~$1.1B.
- Royalty Pharma receives 15% royalty on first $1B annual US sales; Agios retains 3% on sales above $1B.
- Proceeds intended to fund PYRUKYND launches in thalassemia/sickle cell and expand pipeline.
- Transaction closing requires FDA approval by Oct 31, 2024 and other customary conditions.